Skip to main content

Table 3 Hazard ratios of incident cardiovascular disease in the categories of body composition classified using A/G ratio

From: Sarcopenic obesity assessed using dual energy X-ray absorptiometry (DXA) can predict cardiovascular disease in patients with type 2 diabetes: a retrospective observational study

 

HR

(95% CI)

p value

Univariate model

 Normal

1.00 (reference)

–

–

 Sarcopenia

1.43

(0.58–3.52)

0.439

 Obesity

1.56

(0.71–3.43)

0.269

 Sarcopenic obesity

4.50

(1.93–10.46)

0.006

Multivariate model

 Normal

1.00 (reference)

–

–

 Sarcopenia

1.88

(0.75–4.74)

0.179

 Obesity

0.98

(0.44–2.21)

0.969

 Sarcopenic obesity

2.63

(1.10–6.28)

0.030

 HDL cholesterol (mmol/l)

0.21

(0.08–0.56)

0.002

 HbA1c (%)

1.28

(1.09–1.49)

0.002

 eGFR (ml/min/1.73 m2)

0.97

(0.96–0.98)

< 0.001

 ACEIs or ARBs

2.07

(1.11–3.86)

0.022

 DPP4 inhibitors

0.46

(0.23–0.91)

0.025

 History of CVD

2.85

(1.57–5.18)

0.001

Gender-adjusted multivariate model

 Normal

1.00 (reference)

–

–

 Sarcopenia

1.46

(0.57–3.74)

0.429

 Obesity

0.94

(0.42–2.10)

0.870

 Sarcopenic obesity

2.14

(0.88–5.21)

0.093

 HDL cholesterol (mmol/l)

0.23

(0.09–0.62)

0.003

 HbA1c (%)

1.28

(1.10–1.49)

0.001

 eGFR (ml/min/1.73 m2)

0.97

(0.96–0.96)

< 0.001

 ACEIs or ARBs

2.18

(1.17–4.10)

0.014

 DPP4 inhibitors

0.46

(0.23–0.88)

0.020

 History of CVD

2.65

(1.44–4.87)

0.001

 Gender (male = 1)

1.67

(0.87–3.20)

0.126

  1. ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CVD, cardiovascular disease; DPP4, dipeptidyl peptidase 4, CI, confidence interval; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HR, hazard ratio